Prevention of macrovascular disease in type 2 diabetic patients: Blockade of the renin-angiotensin-aldosterone system

Current Diabetes Reviews

Volumn 4, Issue 1, 2008, Pages 63-78

  Thomas, G Neil ^a   Tomlinson, Brian ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme; Cardiovascular disease; Coronary heart disease; Diabetes; Nephropathy; Renin angiotensin aldosterone system; Stroke

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; INSULIN; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE CONTROL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; FALLING; FATIGUE; FOOD; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HEMODYNAMIC MONITORING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYNCOPE; TASTE DISORDER; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENALAPRIL; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 38949207293     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339908783502334     Document Type: Review

References (204)

1. The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia, and newly-diagnosed diabetes. Diabetologia 2003; 46: 608-17.
2. Qiao Q, Hu G, Fuomilehto J, et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003; 26: 1770-80.
3. Thomas GN, Jiang CQ, McGhee SM, et al. Association of vascular risk factors with increasing glycaemia even in normoglycaemic subjects in an older Chinese population: the Guangzhou Biobank Cohort Study. Metabolism 2006; 55: 1035-41.
4. Thomas GN, McGhee SM, Schooling CM, et al. Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: the Hong Kong Cardiovascular Risk Factor Study. J Endocrinol Invest 2006; 29: 528-35.
5. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44: S14-21.
6. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-61.
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
8. Thomas GN, Chook P, Qiao M, et al. Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004; 24: 739-43.
9. Thomas GN, Schooling M, McGhee SM, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol 2007; 66: 666-71.
10. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases-report for mem-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci 2002; 15: 245-52.
11. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
12. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stoke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
13. Gilbert RE, Krum H, Wilkinson-Berka, J, Kelly DJ. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003; 20: 607-21.
14. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
15. Thomas GN, Critchley JAJH, Tomlinson B, et al. Obesity independent of insulin resistance, is a major determinant of blood pressure in nonnoglycaemic Hong Kong Chinese. Metabolism 2000; 49: 1523-8.
16. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-11.
17. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-65.
18. Vaughan DE. AT(1) receptor blockade and atherosclerosis: hopeful insights into vascular protection. Circulation 2000; 101: 1496-7.
19. Chan JCN, Cheung CK, Cockram CS, et al. Atrial natriuretic peptide and renin-angiotensin-aldosterone system in non-insulin-dependent diabetes mellitus. J Hum Hypertens 1994; 8: 451-6.
20. Thomas GN, Critchley JAJH, Tomlinson R, et al. Albuminuria and the reninangiotensin system gene polymorphisms in Type 2 diabetic and in normoglycaemic hypertensive Chinese. Clin Nephrol 2001; 55: 7-15.
21. Price D, Porter L, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-91.
22. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, de Lima J. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int 1975; 8: 325-33.
23. Tsunoda K, Abe K, Goto T, et al. Effect of age on the renim-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterine in plasma. J Clin Endocrinol Metab 1996; 62: 384-9.
24. Belmin J, Levy BI, Michel J-B. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging 1994; 5: 391-400.
25. Nakamaru M, Ogihara T, Higaki J, et al. Effect of age an active and inactive plasma renin in normal subjects and in patients with essential hypertension. J Am Geriatr Soc 1981; 29: 379-82.
26. Takeda R, Morimoto S, Uchida K, Miyamori I, Hashiba T. Effect of age on plasma aldosterone response to exogenous angiotensin II in normotensive subjects. Acts, Endocrinol 1980; 94: 552-8.
27. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A.
28. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003; 42: 911-3.
29. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin- receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92.
30. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-9.
31. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
32. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-oonverting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Am Intern Med 2001; 135: 73-87.
33. Tomlinson B, Young RP, Chan JCN, Chan TYK, Critchley JAJH. Pharmacoepidemiology of ACE inhibitor-induced cough. Drug Saf 1997; 16: 150-1.
34. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000; 22: 1213-24.
35. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet 1997; 349: 747-52.
36. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low-dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 2000; 14: 263-9.
37. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-72.
38. Hollenberg NK. AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease. J Hum Hypertens 2002; 16 (Suppl 3): S59-63.
39. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-92.
40. Pitt B, Poole-Wilson P, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II. J Card Fail 1999; 5: 146-54.
41. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12: 70-88.
42. Matsubara, H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-91.
43. Henrion D, Kubis N. Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: From large arteries to the microcirculation. Hypertension 2001; 38: 1150-7.
44. Schneider MD, Lorell BH. AT(2), judgment day: which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation 2001; 104: 247-8.
45. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-57.
46. Koka V, Wang W, Huang XR, et al. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 2006; 113: 1353-60.
47. de Gasparo M, Siragy HM. The AT2 receptor: fact, fancy and fantasy. Regul Pept 1999; 81: 11-24.
48. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens, 2000; 13: 62S-7S.
49. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-9.
50. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
51. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertens Res 2006; 47: 515-21.
52. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165: 1019-32.
53. Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004; 61: 2728-37.
54. Schwartz JB, Taylor A, Abernethy D, et al. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. J Cardiovasc Pharmacol 1985; 7: 767-76.
55. Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influende of ACE inhibition. J Cardiovasc Pharmacol 1994; 24 (Suppl 3): S61-S9.
56. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989; 7: S11-6.
57. Williams PE, Brown AN, Rajaguru S, et al. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol 1989; 27 (Suppl 2): 11S-215S.
58. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 1998; 34: 457-82.
59. Warner GT, Perry CM. Ramipril: A review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62: 1381-405.
60. Simpson K, Jarvis B. Lisinopril: A review of its use in congestive heart failure. Drugs 2000; 59: 1149-67.
61. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41: 207-24.
62. Culy CR, Jarvis B. Quinapril: A further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002; 62: 339-85.
63. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081-8.
64. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991; 20: 420-7.
65. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-53.
66. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14: S73-86.
67. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
68. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
69. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902.
70. Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59: 1187-206.
71. Wienstock J, Keenan RM, Samanen J, et al. 1-(Carboxybenzyl) imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991; 34: 1514-7.
72. Schambye HT, Hjorth SA, Weinstock J, Schwartz TW. Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor. Mol Pharmacol 1995; 47: 425-31.
73. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62: 1983-2005.
74. Chung O, Csikos T, Unger T. Pharmacologic differences of angiotensin II antagonists. Receptors Cardiovasc Dis 1998; 5: 1-6.
75. Yasar UMD, Forslund-Bergengren CMD, Tybring GP, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71: 89-98.
76. Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20: 2089-93.
77. Uchida S, Watanabe H, Nishio S, et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther 2003; 74: 505-8.
78. Waldmeier F, Flesch G, Muller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27: 59-71.
79. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-182: 453-6.
80. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56: 1039-44.
81. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-8.
82. Plosker GL, Foster RH, Eprosartan: a review of its use in the management of hypertension. Drugs 2000; 60: 177-201.
83. Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 2000; 16: 227-50.
84. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
85. Mallion JM, Siche JP, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-64.
86. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999; 19: 95S-101S.
87. von Bergmann K, Laeis P, Puchler K, et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 2001; 19 (Suppl 1): S33-40.
88. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000; 40: 1355-64.
89. Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 2000; 16: 227-50.
90. Plosker GL, Foster RH. Eprosartan: a review of its use in the management of hypertension. Drugs 2000; 60: 177-201.
91. Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther 1999; 66: 367-73.
92. Zannad F, Matzinger, A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-43.
93. McInnes GT. Angiotensin II antagonism in clinical practice: experience with valsartan. J Cardiovasc Pharmacol 1999; 33 (Suppl 1): S29-32.
94. Burrell LM, Johnston CI. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs Aging 1997; 10: 421-34.
95. Conlin PR. Angiotensin II antagonists in the treatment of hypertension: more similarities than differences. J Clin Hypertens 2000; 2: 253-7.
96. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-26.
97. McInnes GT, O'Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-80.
98. Okereke CE, Messerli FH. Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. Am J Geriatr Cardiol 2001; 10: 42-9.
99. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003; 21 (Supol 2): S43-6.
100. Tomlinson B, Young RP, Chan JCN, Chan TYK, Critchley JAJH. Pharmacoepidemiology of ACE inhibitor-induced cough [letter]. Drug Saf 1997; 16: 150-1.
101. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS38). Br Med J 1998; 317: 703-13.
102. Man in't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens 1997; 15 (Suppl): S27-33.
103. McInnes GT. Angiotensin II antagonism in clinical practice: experience with valsartan. J Cardiovasc Pharmacol 1999; 33: S29-32; discussion S41-3.
104. Pool JL, Guthrie RM, Littlejohn 3rd TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-70.
105. Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414-7.
106. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators [published erratum appears in Am J Hypertens 1998; 11: 736]. Am J Hypertens 1998; 11: 445-53.
107. Lindholm LH, Hansson L, Ekhom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-5.
108. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
109. Tatti P, Pahor M, Byington R, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Cam 1998; 21: 597-603.
110. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-92.
111. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
112. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45: 813-27.
113. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
114. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
115. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
116. Pfeffer MA, Swedberg K., Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
117. Staossen JA, Thijs L, Birkenhager WH. VALUE: analysis of results. Lancet 2004; 364: 931.
118. Weber MA, Julius S, Kjekldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.
119. Dahlof B, Devereux R B, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
120. Staessen IA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-76.
121. Hoieggen A, Alderman MH, Kieldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9.
122. Lindbolm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
123. American Heart Association. Heart and Stroke Statistical Update. Dallas, Texas, American Heart Association, 2000. 2001.
124. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87 (Suppl VI): 40-8.
125. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34: 83-9.
126. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21: 1967-78.
127. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
128. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blocken in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-38.
129. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee (in Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
130. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Loasartan Heart Failure Survival Study ELITE H. Lancet 2000; 355: 1582-7.
131. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies fOr Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
132. Greenberg BH. Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. Circulation 1999; 100: 1032-4.
133. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure, and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.
134. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
135. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
136. Cohn JN, Tognoni G, for the Val-HeFT Investigators. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT) [abstract]. Circulation 2000; 102.
137. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heat failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414-21.
138. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
139. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
140. Cohn JN, Tognoni G, for the Val-HeFT Investigators. Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity and Mortality in Heart Failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2000: 102.
141. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
142. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-45.
143. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
144. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-oontrolled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
145. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
146. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTI-MAAL randomised trial. Optimal Trial in Myocardial Infraction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-60.
147. Bosch J, Yusuf S, Pogue J, et al. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702.
148. Berthet Y, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004; 13: 7-13.
149. Hanason L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
150. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
151. Papademetriou V, Farsang C, Ehnfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-80.
152. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitreadipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.
153. Ismail N. Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28.
154. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-33.
155. Critchley JA, Zhao HL, Tomlinson B, et al. Management of nephropathy in patients with type 2 diabetes. Chin Med J (Engl) 2002; 115: 129-35.
156. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22.
157. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 2001; 345: 870-8.
158. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001; 345: 851-60.
159. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
160. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.
161. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2003; 26 (Suppl 1): S94-S8.
162. US Renal Data System. Atlas of end-stage renal disease in the United States. 1995. Bethesda, Md, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2002.
163. Li LS. End-stage renal disease in China. Kidney Int 1996; 49: 287-301.
164. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25: 107-12.
165. Chan JCN, Cockram CS. Diabetes in the Chinese population and its implications for health care. Diabetes Care 1997; 20: 1785-90.
166. Guidelines subcommittee. 1999 World Health Organization-International Society for Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
167. Luno J, Garcia de Vinuesa S, Gomez-Campdera F, Lorenzo I, Valderrabano F. Effects of antihypertensive therapy on progression of diabetic nephropathy. Kidney Int 1998; 68 (Suppl): S112-S9.
168. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889-96.
169. Kshimagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled. trials. Am J Kidney Dis 2000; 35: 6915-707.
170. Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and Type 2 diabetic, nephropathy: A meta-analysis, Pharmacotherapy 2003; 23: 909-15.
171. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2602; 106: 672-8.
172. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
173. Leung WY, So WY, Tong PC, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2004; 19: 2519-25.
174. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
175. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
176. Barnett AH, Bain SC, Router P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
177. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003; 26: 707-20.
178. Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001; 40: 605-14.
179. Bindschedler M, Degen P, Flesch G, de Gaspato M, Preiswerk G. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997; 52: 371-8.
180. Stangier J, Su CA, Hendriks MG, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000; 40: 1373-9.
181. Chan P, Tomlinson B, Huang TY, et a. Double-blind comparison of losartan, lisinopril, and metotazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 253-7.
182. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25: 73-6.
183. Abbosh J, Anderson JA, Levine AR, Kupin WL. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 1999; 82: 473-6.
184. Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res 1996; 57: 392-407.
185. Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Clin Res 1998; 1: 147-59.
186. McInnes GT. Clinical advantage of valsartan. Cardiology 1999; 91: 14-8.
187. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
188. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237-42.
189. Irons RK, Kumar A. Valsartan-induced angioedema. Am Pharmacother 2003; 37: 1024-7.
190. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment Arch Intern Med 2004; 164: 910-3.
191. Csajka C, Buclin T, Brunner HF, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Chn Pharmacokinet 1997; 31: 1-29.
192. Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism an patients with essential hypertension. J Hypertens 1999; 17: 1033-9.
193. Calvino J, Lens XM, Romero R, Sanchez-Guisande D. Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000; 15: 82-6.
194. Ducloux D, Saint-Hillier Y, Chalopin JM. Effect of losartan on haemoglobin concentration in renal transplant recipients-a retrospective analysis. Nephrol Dial Transplant 1997; 12: 2683-6.
195. Reid JL, MacFadyen RJ, Squire IB, Lecs KR. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am Heart J 1993; 126: 794-7.
196. Capewell S, Capewell A. 'First dose' hypotension and venodilatation. Br J Clin Pharmacol 1991; 31: 213-5.
197. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995; 6: 219-28.
198. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens 1999; 12: 195S-203S.
199. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-50.
200. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
201. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control an hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
202. Andraws R, Brown DL. Effect of inhibition of the Renin-Angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-12.
203. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
204. Kelly JG, O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin Pharmacokinet 1990; 19: 177-96.